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Abstract: Acute gastroenteritis is a very common disease. It causes significant mortality in 
developing countries and significant economic burden to developed countries. Viruses are 
  responsible for approximately 70% of episodes of acute gastroenteritis in children and rotavirus 
is one of the best studied of these viruses. Oral rehydration therapy is as effective as i  ntravenous 
therapy in treating mild to moderate dehydration in acute gastroenteritis and is strongly 
r  ecommended as the first line therapy. However, the oral rehydration solution is described as an 
underused simple solution. Vomiting is one of the main reasons to explain the underuse of oral 
rehydration therapy. Antiemetics are not routinely recommended in treating acute gastroenteritis, 
though they are still commonly prescribed. Ondansetron is one of the best studied antiemetics 
and its role in enhancing the compliance of oral rehydration therapy and decreasing the rate 
of hospitalization has been proved recently. The guidelines regarding the recommendation on 
antiemetics have been changed according to the evidence of these recent studies.
Keywords: gastroenteritis, vomiting, antiemetic, ondansetron, rotavirus, oral rehydration 
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Introduction
Gastroenteritis is defined as the inflammation of the mucus membranes of the 
g  astrointestinal tract and is characterized by diarrhea or vomiting. It is a common child-
hood disease. Children in developing countries are particular at risk of both morbidity 
and mortality. Worldwide, gastroenteritis affects 3 to 5 billion children each year, and 
accounts for 1.5 to 2.5 million deaths per year or 12% of all deaths among children 
less than 5 years of age.1–3 In developed countries, such as the United States, acute 
gastroenteritis seldom causes deaths, however, it still accounts for 300 deaths per year.2 
Moreover, it puts a heavy burden on the health care system. Acute gastroenteritis causes 
1.5 million visits to primary care providers each year and 220,000 hospital admis-
sions for children under the age of 5 years; that is 10% of all the hospital admissions 
of children in the United States.2 In general, developing countries have a higher rate 
of hospital admissions as compared to developed countries. In the United States, the 
admission rate is 9 per 1000, per annum, for children younger than 5 years old.4 When 
compared to the United Kingdom and Australia, the admission rates are around 12 
to 15 per 1000 per annum.5,6 However, the rate increases dramatically to 26 per 1000 
per annum in China.7 This may be due to the facts that children in   developed coun-
tries have a better nutrition status and better primary care. The difference can also be 
explained by the fact that, the incidence of acute gastroenteritis is significantly higher 
in developing countries than the industrialized countries.8 Interestingly, Hong Kong Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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is a developed city, and yet the admission rate is even higher 
than many of the developing countries.9 This may reflect that 
the decision of admission does not simply depend on the 
clinical situations, but it can also be affected by the parents’ 
wishes and other social factors.
Etiology
Viruses are the most important etiology and are responsible 
for approximately 70% of the episodes of acute gastroenteritis 
in children.10 There are over 20 different types of viruses 
that have been identified as etiological agents.11 Worldwide, 
rotavirus is still the most common virus causing this disease 
and accounts for some 30% to 72% of all the hospitalizations 
and 4% to 24% of acute gastroenteritis at the community 
level.12–15 Virtually all children have been infected with rota-
virus by the age of 3 years.16 Rotavirus infection is seasonal 
in temperate climates, peaking in late winter, although it 
occurs throughout the year in the tropics. The peak age for 
infection ranges from 6 months to 2 years. Other common 
viruses causing gastroenteritis include calicivirus, adenovirus 
and astrovirus. Globally these viruses are responsible for 
diarrhea episodes in hospitalized children, with detection 
rates varying from 3.2%–29.3%, 1%–31%, and 1.8%–16%, 
respectively.17–20 Rates of virus infection are similar in both 
developed and less developed countries.21 Bacterial infection 
accounts for 10% to 20% of all the acute gastroenteritis.22 
The most common bacterial causes are, Salmonella   species, 
Campylobacter species, Shigella species and Yersina species. 
Vibrio cholerae remains a major cause of diarrhea, especially 
after a disaster where sanitation is compromised. Giardia 
lamblia is the most common protozoal infection that causes 
gastroenteritis, although it tends to be associated with more 
persistent diarrhea. Other protozoa include Cryptosporidium 
species and Entamoeba histolytica. However, less developed 
countries have a higher rate of parasites and Escherichia 
coli infection which are both relatively uncommon in the 
i  ndustrialized countries.21 This indicates that improvement 
in sanitation will not decrease the disease prevalence of 
viral infection but can help in prevention of parasites and 
bacterial infections.
Rotavirus as a prototypic  
virus for gastroenteritis
Rotavirus is a prototypical virus because it is the most c  ommon 
virus that causes acute gastroenteritis in   children which 
results in hospitalization and treatment with   intravenous fluid. 
According to the data from the United States, approximately 
410,000 physician visits are due to the rotavirus infection, 
the cause of 205,000 to 272,000   emergency department 
v  isits, which results in 55,000 to 70,000 hospitalizations.23 
In the United States, 1 in 67–85   children will be hospitalized 
because of rotavirus infection by the age of 5 years.24 On the 
other hand, Hong Kong has a very high rate of   hospitalization. 
By the age of 5 years, the c  umulative risk is 1 in 24, a figure 
that is 3 times higher than the that of the United States.9 
For each admission in the United States, the hospital costs 
range from $2999 to $3400 with the family costs being $359 
which includes the   caregivers loss of work.24–26 In Hong 
Kong, admission costs are less expensive although they are 
not   unsubstantial at $1868 (US) for each admission and 
$120 for family   expenses.9 Adding in the prevalence of the 
disease,   gastroenteritis causes a   significant economic burden 
to the health care system. As to the severity of the disease, a 
study that included 234 hospitalized children infected with 
  rotavirus, 63% of them had diarrhea, vomiting and fever, 21% 
had diarrhea and vomiting, 7% had diarrhea and fever, 4% 
had vomiting and fever, 3% had fever alone, 2% had   vomiting 
alone and 0.4% had diarrhea alone.27 In general, 90% of the 
hospitalized patients had vomiting. Vomiting is one of the 
most important symptoms for considering failure of oral 
rehydration therapy and requiring intravenous therapy.28,29
Oral rehydration therapy versus 
intravenous therapy
The American Academy of Pediatrics (AAP), Centers for 
Disease Control and Prevention (CDC), European Society 
for Pediatric Gastroenterology and Nutrition, and the World 
Health Organization (WHO) all strongly support the use 
of oral rehydration therapy as the first-line therapy for the 
treatment of acute gastroenteritis, except in cases of severe 
dehydration.2,30–32 The effectiveness of oral r  ehydration 
  therapy in treating acute gastroenteritis, with mild to 
  moderated dehydration, has been demonstrated by many 
randomized controlled trials. In a Cochrane meta-analysis of 
17 trials from 1982 to 2005, in which 9 trials were from the 
developed countries, 7 trials from developing countries and 
1 trial involving developed and less developed countries.33 
Included in this analysis were more than 1800 participants. 
The data showed that there were no important clinical 
d  ifferences between oral hydration therapy and intravenous 
therapy for rehydration secondary to acute gastroenteritis 
in children; and that children treated with oral rehydration 
therapy spent less time in hospitals. Moreover, patients 
receiving intravenous therapy had a 2.5% risk of phlebitis that 
did not occur in the oral rehydration group. Importantly, this 
result is unlikely to change with further trials because there Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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is already adequate power to support the observed results 
and further research comparing oral rehydration therapy and 
intravenous therapy is not warranted and may be unethical. 
The effectiveness of oral rehydration therapy is not isolated 
to just clinical trials it can also be reflected in the decreased 
mortality rate. In 1970’s the diarrheal illness related deaths 
were 4.6 million/year worldwide.34 After the promotion 
of oral rehydration therapy by World Health Organization 
(WHO) at the end of 1970’s, the diarrheal illness related death 
rate dropped to 3.3 million/year in 1980’s, with a further drop 
to 2.5 million/year in 1990’s.35
The oral rehydration solution is regarded as one of 
the most important medical advances of the 20th century. 
Although there is much evidence to support the usage of 
oral rehydration with numerous published guidelines and 
many professional organizations recommending its use, 
oral rehydration solution is still described as an underused 
simple therapy.36 Intravenous therapy is still often chosen 
rather than oral rehydration therapy. Data from Europe, 
Australia and Canada show that 80% to 94% of hospitalized 
children do not have any signs of dehydration and yet they 
still receive intravenous therapy.37–39 Data from Hong Kong, 
that assessed more than 7000 episodes of admission due to 
  gastroenteritis in children under 5 years of age, also showed 
that only 1.3% to 8.4% had signs of dehydration and yet up 
to 48% of the patients received intravenous therapy.40 The 
rate of   intravenous therapy was even higher in the rotavirus 
group. According to a recent survey, 45% of physicians 
still   preferred intravenous fluid therapy rather than oral 
  rehydration therapy in treating moderate   dehydration in 
acute gastroenteritis.41 However, judging the e  ffectiveness of 
oral rehydration therapy and the overuse of the i  ntravenous 
th  erapy, any treatments in acute gastroenteritis should 
improve the success or compliance of oral rehydration 
therapy as the top priority. Safety and cost are also important 
issues. Successful oral rehydration therapy always means 
that the children can be managed in the community. It is 
more pleasant for the children and more comfortable for the 
caregivers. Oral rehydration therapy also helps to save money 
by reducing the hospitalization costs.
Reasons of underused oral 
rehydration therapy
The reasons for the underuse of oral rehydration therapy are 
not fully understood. In 2002 Ozuah and colleagues published 
a national random survey of emergency physicians selected 
from the mailing list of the AAP that addressed this issue.29 
A total of 176 physicians responded (73% response rate). 
Their responses can be divided into four categories: the 
physician factors; patient factors; parental concern; and 
environment or social factors. Regarding the physician fac-
tors; in contrast to the group of physicians unfamiliar with 
the AAP guidelines, the f  amiliar group was more likely to 
use oral rehydration therapy in   scenarios of mild dehydration 
(81% versus 66%) and   moderate dehydration (25% versus 
10%). Parental c  oncern about dehydration (disregarding the 
actual hydration status of the patients) would make 31% of 
the emergency department physicians choose intravenous 
therapy over oral rehydration therapy. A crowded or emer-
gency department with long waiting times would cause 22% 
of the physicians to choose intravenous therapy. Regarding 
the severity of d  ehydration, 49.4% of emergency department 
physicians would offer intravenous therapy even in moderate 
de  hydration. In terms of symptoms, only 8% of the emer-
gency department p  hysicians would consider intravenous 
therapy when   diarrhea was a major symptom. On the other 
hand, patients refusing to drink was the most likely reason 
for choosing i  ntravenous therapy (up to 96%). Vomiting 
was the second most important reason given for intravenous 
therapy, with up to 85% of the physicians being more likely 
to use intravenous therapy when vomiting was the predomi-
nant symptom. In another study, up to 36% of the surveyed 
physicians believed that vomiting was a contraindication for 
oral rehydration therapy.28
Approximately 70% of all children with   gastroenteritis also 
present with vomiting.37 According to our own   unpublished 
data ( of more than 7000 episodes of   hospitalization in Hong 
Kong due to acute gastroenteritis in children younger than 
5 years of age) 62% of gastroenteritis patients presented 
with vomiting. Up to 82% of rotavirus infected children 
presented with vomiting, a figure that was very similar to 
the study by Staat and colleagues in 2002.27 In terms of the 
episodes and duration of vomiting in gastroenteritis patients, 
the mean number of vomiting episodes was 4.91/24 hours 
and for a duration of 1.84 days. In summary this may partly 
explain why the oral rehydration solution is an underused 
simple solution.
The pathophysiology of vomiting 
and the mechanisms of antiemetic 
medications
Vomiting is usually defined as a violent expulsion of the 
stomach contents through the mouth and being a very 
unpleasant symptom. It can also be associated with nau-
sea and retching. The mechanism of vomiting has been 
well characterized, first by Borison and Wang in 1953.42 Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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The vomiting center controls and integrates the act of 
v  omiting. It is located in the lateral reticular formation of 
the medulla oblongata, which is close to other centers that 
regulate   respiration, vasomotor, and other autonomic func-
tions. These centers too may also play an additional role 
in vomiting. Emetic stimuli can be transmitted directly to 
the   vomiting center or through the chemoreceptor trigger 
zone. The c  hemoreceptor trigger zone, located in the area 
postrema of the fourth ventricle and outside the blood-brain 
barrier, is exposed to both cerebrospinal fluid and blood.43 
This would allow the chemoreceptor trigger zone to pick 
up the c  hemical signals from both cerebrospinal fluid and 
blood stream (such as bacterial toxins or form metabolic 
abnormalities that occur with uremia) and act as an afferent 
limb to the vomiting center; however, it cannot indepen-
dently mediate the act of vomiting without the interaction of 
vomiting center. On the other hand, the vomiting center does 
not only receive information from the chemoreceptor trigger 
zone, it can also receive information and stimulation from 
the cerebral cortex and limbic system, the vestibular system, 
and the vagal and splanchnic afferents.42,44,45 Psychological 
stress such as fear can act on cerebral cortex and limbic 
system to induce vomiting via the vomiting center. Vomiting 
due to motion sickness develops consequent to stimulation 
of the vestibular system, with impulses that travel from the 
labyrinth of the inner ear to the vomiting center.
However,  the  exact  mechanism  of  vomiting  in 
  gastroenteritis is not known; although it is thought to be due 
to the peripheral stimuli arising from the g  astrointestinal 
tract primarily via the vagus nerve or via serotonin 
  stimulation of the 5-hydroxytryptamine 3 (5HT3) recep-
tors in the gut.46–49 In acute gastroenteritis, intestinal irrita-
tion can damage the gastrointestinal mucosa and result in 
the release of   serotonin from the enterochromaffin cells. 
This serotonin acts on the 5HT3 receptors of the vagal 
afferent nerves in the g  astrointestinal tract,49 which are 
then transmitted to the vomiting center directly or via the 
chemoreceptor trigger zone. The vomiting center then sends 
efferent impulses to the diaphragm, abdominal muscles, and 
visceral nerves of the stomach and esophagus to produce 
vomiting.50,51 These events typically include: an increase 
in salivation; a decrease in gastric tone that results in the 
sensation of nausea; nonperistaltic contractions in the small 
intestine; regurgitation of the intestinal contents into the 
stomach; contractions of the respiratory and abdominal 
muscles; and the descent of the diaphragm against a closed 
glottis such that the gastric contents are forced up into the 
esophagus and out through the mouth.
Antiemetic therapy aims at: depressing the vomiting 
center; depressing the chemoreceptor center; inhibiting the 
impulses from chemoreceptor zone to vomiting center; and/or 
inhibiting impulses from peripheral receptors to the vomiting 
center. All the areas involved in the   pathogenesis of vomit-
ing are rich in serotoninergic, dopaminergic,   histaminic, and 
muscarinic receptors.45 Dopamine an  tagonists suppress pro-
emetic stimuli by blocking D2 receptors in the chemoreceptor 
trigger zone. 5-HT3 antagonists have been more recently 
developed to block the nausea and v  omiting reflexes medi-
ated by stimulation of 5-HT3 receptors in both the small 
intestine and the chemoreceptor center.   Antihistamines, 
although widely used for migraine, are   generally recom-
mended for motion sickness as they act at the level of the 
vestibular apparatus.43,52 Anti-cholinergic agents such as 
atropine and hyoscine are relatively ineffective in the treat-
ment or prevention of vomiting due to causes other than 
motion sickness.52–54 The mechanism of action is not clearly 
understood in some antiemetic medications such as dexam-
ethasone and trimethobenzamide.
The use of antiemetics  
in acute gastroenteritis
In 1996, the AAP made the f  ollowing statement: “The 
committee did not evaluate the use of antiemetic drugs. 
Consensus opinion is that antiemetic drugs are not needed. 
Physicians who feel that antiemetic therapy is indicated in a 
given situation should be aware of potential adverse effects”.31 
In 2003, the C  enters for Disease Control and Prevention 
(CDC) released an updated s  tatement regarding the usage 
of antiemetics. It also   concluded that a  ntiemetics are usually 
unnecessary. Reliance on ph  armacologic agents shifts the 
therapeutic focus away from appropriate fluid, electrolyte, 
and nutritional therapy, that can result in adverse events, and 
can add unnecessarily to the economic burden of the illness.2 
Notwithstanding the lack of an official recommendation for 
their use, antiemetics are still commonly prescribed among 
different specialties and countries in the management of 
acute gastroenteritis.
Antiemetics are often used because vomiting is an 
unpleasant and a distressing symptom which can increase the 
likelihood of dehydration, electrolyte imbalance, pulmonary 
aspiration, and most importantly the need for intravenous 
hydration or hospitalization.55–58 The reasons why antiemetics 
are not commonly recommended for gastroenteritis related 
vomiting are because vomiting is self-limiting, vomiting 
is a normal physiological reaction for ridding the body of 
toxic substances, and antiemetics can have adverse side Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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effects.10,38,59 In addition, the newer antiemetics are also 
costly.
O’Loughlin and colleagues prospectively surveyed all 
children with acute vomiting or diarrhea who were   admitted 
to a pediatric inpatient facility in Newcastle, NSW,   Australia, 
during a 12-month period. The authors found that antiemetic 
medication was administered to 21 (9%) of 231 children 
prior to admission.59 Elliott and colleagues found that 
antiemetic medications were prescribed for the treatment 
of acute g  astroenteritis in 9 (5.5%) of 164 children prior to 
admission to the Royal Alexandra Hospital for Children in 
Sydney, NSW, Australia, during a 6-month period.38 Nelson 
and colleagues interviewed the caregivers of 105 pediatric 
in-patients with gastroenteritis in Hong Kong where up to 
73% had seen one or more primary care practitioners prior 
to admission to hospital, and 29% of cases were prescribed 
antiemetics.60
In 2002, Kwon and colleagues conducted a national 
survey to address this problem in the United States among 
emergency physicians, general pediatricians and pediatric 
emergency physicians.61 In this study, 79.2% of emergency 
physicians would prescribe antiemetics as compared to 52.2% 
of general pediatricians and 55.2% of pediatric   emergency 
physicians. The use of antiemetics by emergency   physicians 
was greater than the other two specialties (P , 0.001). 
The most commonly nonexclusive reason for prescribing 
antiemetic use was to prevent the w  orsening dehydration 
and the need for subsequent intravenous   fluids or admission 
(72.0%). This was followed by patient comfort (59.0%), 
assurance/d  ocumentation of oral liquid trial in e  mergency 
department/clinic/office before   discharge (35.5%), and 
parental   concerns/pressures (29.4%). Albano and   colleagues 
conducted a similar survey to look at the   practice of Italian 
hospital pediatricians and family p  hysicians.62   Approximately 
71% of hospital pediatricians would use antiemetic 
m  edications as compared to 96% of the family physicians. 
When   comparing the reasons for prescription by family 
physicians versus hospital pediatricians, the latter were more 
likely to prescribe antiemetics in order to increase the suc-
cess rate of oral rehydration therapy (48%), whereas family 
physicians prescribed them to increase patient comfort or to 
reduce concerns of parents (46%).
Pfeil and colleagues investigated the prescription pattern 
of antiemetic medications in 0- to 9-year-old children with 
infectious gastroenteritis in several industrialized countries 
during 2005.63 The authors retrospectively retrieved data 
from four national and international databases which showed 
that between 2% and 23% of children with gastroenteritis 
received prescriptions for antiemetic medications (United 
States, 23%; Germany, 17%; France, 17%; Spain, 15%; Italy, 
11%; Canada, 3%; United Kingdom, 2%).
In summary, antiemetic drugs are frequently used 
in   children with gastroenteritis by physicians in various 
s  pecialties and in various countries in spite of the lack of an 
official recommendation for their use.
Antiemetic medications
Serotonin 5HT3 receptor antagonists
Ondansetron
Ondansetron is a carbazole derivative that has been available 
since 1991. It is one of the best known potent serotonin 5-HT3 
receptor-antagonists that blocks receptors at the vagus and 
sympathetic nerves together with the chemoreceptor trigger 
zones.64 It has no antidopaminergic properties. The efficacy 
of ondansetron for chemotherapy-induced or postoperative 
vomiting in the pediatric population is well documented.65,66 
It also has promising effects in patients with vomiting 
due to migraines, procedural sedation with ketamine and 
a  cetaminophen poisoning.67–69
These positive results initiated investigations for their 
use in gastroenteritis related vomiting. However, only a few 
randomized controlled trials regarding its use in pediatric 
gastroenteritis have been published. In 2008, DeCamp and 
colleagues published a meta-analysis in order to address this 
question.70 The investigators reviewed prospective   controlled 
trials only and looked at the emesis cessation, use of 
i  ntravenous fluid for rehydration, hospital admission, return 
to care, and medication adverse effects as the p  rincipal out-
comes. There were 11 articles that met the inclusion   criteria. 
Ondansetron has the greatest number of studies that met the 
criteria (n = 6, participants = 745).55,71–75 All of the studies 
were conducted in the emergency department s  etting, except 
the study by Cubeddu and colleagues that was performed in 
an in-patient setting.55 The majority of studies included only 
children but the study by Reeves and colleagues also included 
patients up to 22 years of age.72 Among the six   studies, 
the two studies published by Reeves et al and F  reedman 
et al required dehydration as an inclusion criterion.72,74 The 
study published by Roslund and colleagues and Stork and 
colleagues, required both dehydration and failure of oral 
rehydration as the inclusion criteria.71,75 However, all the 
participants in the study by Stork and colleagues received 
intravenous therapy.71 In all except one study, only one dose 
of ondansetron was administered during the study period. 
The study by Ramsook and colleagues provided families with Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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additional doses for home use.73 Routes of admi  nistration 
and dosing varied across studies. There were 3 studies using 
intravenous ondansetron. Among these 3 studies, both Stork 
et al and Reeves et al used a dose of 0.15 mg/kg,71,72 whereas 
Cubeddu and colleagues used a dose of 0.3 mg/kg.55 Among 
the 3 studies of oral ondansetron, Freedman et al and Roslund 
et al used similar weight-based dosing ranging from 2 to 
8 mg,74,75 and Ramsook and colleagues used age-based dosing 
ranging from 1.6 to 4.0 mg.73 The follow-up period ranged 
from 24 hours to 2 weeks.
Five studies (659 participants) reported whether patients 
continued to have emesis in the emergency department after 
administration of the study drug. Using data from these 
five   studies, the relative risk (RR) for vomiting after the 
o  ndansetron compared to placebo was 0.45 ( 95% confidence 
interval [CI]: 0.33–0.62; number needed to treat [NNT] = 5).70 
Four studies (489 participants) reported the use of intravenous 
fluid. However, the indications for intravenous fluid varied 
from study to study and included persistent emesis, refusal 
to drink, and persistent or worsening states of dehydration. It 
also showed a statistically significant reduction in the RR of 
intravenous fluid use for patients who received ondansetron 
versus placebo (RR, 0.41; 95% CI: 0.28–0.62; NNT = 5).70 
Five trials (662 participants) included hospital admission 
as an outcome. Patients who received ondansetron had a 
  statistically significant decrease in risk of immediate hospital 
admission (RR, 0.52; 95% CI: 0.27–0.95; NNT = 14).70 Five 
trials (612 participants) assessed whether patients returned 
to outpatient care during the study period. Ondansetron 
use did not significantly affect return to care (RR, 1.34; 
95% CI: 0.77–2.35).70 With regard to the RR of admission 
  during the whole study period, there was also no significant 
d  ifference between the treatment group and the controlled 
group (RR, 0.69; 95% CI: 0.43–1.11).70
Five studies documented the severity of diarrhea after 
ondansetron administration. Overall, three studies have 
documented an increased severity of diarrhea after the 
ondansetron. Freedman and colleagues reported an increase 
in diarrhea during the emergency department stay although 
they did not evaluate the incidence of diarrhea during follow-
up.74 Ramsook and colleagues did not detect any difference 
in the severity of diarrhea during the emergency   department 
stay but reported an increase in severity in 48 hours after 
discharge from the emergency department.73 Cubeddu and 
colleagues also reported more diarrhea episodes in the 
24 hours after the ondansetron administration.55 On the other 
hand, the studies by Roslund et al and Reeves et al detected no 
  differences in diarrheal episodes 5 to 7 days after discharge 
from the emergency department.72,75 In summary, although an 
increase in diarrhea was noted in the ondansetron group up to 
48 hours after administration, no difference in frequency was 
detected afterwards. No other adverse event was sy  stemically 
evaluated and no other adverse effects were common across 
different studies.
The most recent Cochrane meta-analysis was   performed 
by Alhashimi and colleagues who used very strict   inclusion 
criteria and excluded the studies by Reeves et al and Stork 
et al.76 The authors came to a similar conclusion, that 
ondansetron may reduce the amount of acute vomiting as well 
as reducing the number of children who required i  ntravenous 
rehydration, and admission for acute   gastroenteritis. 
  However, participants in the ondansetron group did have 
more diarrhea than in the placebo group.
There was one randomized, double blind, placebo 
c  ontrolled trial that was published in 2009, however, it was not 
included in the previous meta-analysis.77 This study was also 
performed in emergency department. A total of 109 children 
aged from 5 months to 8 years who had   nonbilious, nonbloody 
vomiting at least 4 times in the last six hours, who could not 
tolerate oral feeding, who had at least 4 e  pisodes of diarrhea 
in the previous 24 hours, and who had mild to moderate dehy-
dration were recruited. Oral ondansetron (0.2 mg/kg/dose) 
was administered at 8 hourly intervals with a total of 3 doses. 
The frequency of vomiting was s  ignificantly lower among 
the children who received ondansetron than among those 
who received placebo (0.36 versus 1.33, P , 0.001 and 0.2 
versus 1.66, P , 0.001 at four hours and twenty-four hours 
respectively). Weight gain in the ondansetron group was 
significantly higher than that of the placebo group at eight 
hours after intervention. At the end of the study, 5.4% (3/55) 
in the ondansetron group and 18.6% (10/54) in the placebo 
group failed oral reh  ydration therapy (RR = 0.29; 95% CI: 
0.086–1.01; P = 0.04). The authors found that the absolute 
risk of reduction and the number needed to treat were 13.2% 
and 8%, in terms of hospitalization and/or intravenous rehy-
dration treatment. In terms of side effects, the children who 
received ondansetron had more episodes of diarrhea while 
undergoing oral rehydration than those who received placebo 
at 24 hours (P = 0.04). All of the randomized controlled tri-
als (RCT) evaluating the efficacy of ondansetron in acute 
gastroenteritis are summarized in Table 1.
The safety profile of ondansetron is favorable, as in the 
treatment of gastroenteritis, diarrhea is the most common 
and only reported side effect according to the 7 randomized 
controlled trials involving 854 participants. However, 
d  iarrhea associated with this treatment is usually mild and Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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self-limiting. Furthermore, the study by Bryson, evaluating 
the use of ondansetron in the treatment of postoperative 
emesis in 1900 patients, found the incidence of adverse 
events was similar to that of placebo.78 It did not cause extra-
paramidal reactions or sedation.56 However, in other large 
clinical trials, including some pediatric patients, documented 
headache as the most common adverse effect, followed by 
fatigue and constipation.79
Ondansetron has a good tolerability. It is completely 
and rapidly absorbed from the gastrointestinal tract, and 
then metabolized by the cytochrome P450 enzyme system 
with subsequent glucuronide or sulfate conjugation in 
the liver.80–82 It also has a low potential for drug interac-
tions. Peak plasma concentration occurs approximately 
2 hours post oral and the bioavailability is approximately 
60%.80 Peak plasma co  ncentration occurs 40 minutes 
post i  ntramuscular a  dministration, and 10 minutes post 
i  ntravenous a  dministration. It has a half-life of 2 to 6 hours.81 
Its antiemetic duration of action is variable from 2 to 8 hours 
with standard dosing. The recommended intravenous dose 
of ondansetron is 0.1 to 0.15 mg/kg body weight, up to a 
maximum of 4 mg.81 The recommended oral dose is 2 mg 
for children weighing 8 to 15 kg, 4 mg for children w  eighing 
15 to 30 kg and 8 mg for children   weighting .30 kg up 
to a maximum of 3 times/day. However, a single dose of 
oral ondansetron is usually sufficient for the treatment of 
g  astroenteritis related vomiting.
The main drawback of ondansetron has been the cost; 
however, a generic form of ondansetron has recently been 
available and so cost is no longer a barrier to its use. In 
addition, the use of the medication can minimize the need 
for hospitalization (NNT = 14) and intravenous therapy 
(NNT = 5).70 Even so there has been no formal study in terms 
of the cost saving, although judging from the very high costs 
associated with hospitalization, the use of this medication 
may reduce the overall health care costs of treating patients 
with gastroenteritis.
Other 5HT3 receptor antagonists
These include granisetron, tropisetron, dolasetron and 
ramosetron. These medications have been evaluated in the 
management of post-operative and chemotherapy related 
nausea and vomiting. One trial comparing granisetron and 
ondansetron and another comparing granisetron,   tropisetron 
and ondansetron in children undergoing chemotherapy 
found no significant differences in efficacy outcomes.83,84 
Three trials have compared dolasetron and ondansetron 
in children undergoing surgical procedures and these also 
showed no significant difference in terms of efficacy.85–87 
There has been no controlled trial directly comparing 
ramosetron and on  dansetron. Moreover, none of these new 
5HT3 receptor antagonists have evaluated in the treatment 
of gastroenteritis related vomiting. Although one advantage 
of these   medications is that their longer half-life, the main 
disadvantage is they are usually more expensive.
Other antiemetic medications
Antihistamine
Dimenhydrinate
Dimenhydrinate is a first generation H1 receptor antagonist. 
It not only blocks the H1 receptors in the nucleus tractus 
solitarius, it also blocks the muscarinic-cholinergic receptors 
in both the vestibular apparatus and the vomiting center.43,82 
Dimenhydrinate is very convenient to use because it can be 
given via oral, rectal, intramuscular or intravenous routes.88 
The recommended dose is 1.25 mg/kg body weight, with a 
maximum of 50 mg.43,82 It has also been used for the   treatment 
and prevention of motion sickness, radiation sickness, 
  disturbances of labyrinthine function, and post operative 
nausea and vomiting.89–92 The cost of dimenhydrinate is a 
lot less expensive when compared to ondansetron. The main 
concern for the use of dimenhydrinate in the treatment of 
acute gastroenteritis related vomiting is its sedative effect. 
It can jeopardize the oral intake of rehydration fluids and 
further aggravate dehydration. There have been no efficacy 
studies for dimenhydrinate in gastroenteritis until recently. 
In 2009, Uhlig and colleagues published a prospective, ran-
domized, placebo controlled, multicenter trial investigating 
dimenhydrinate in children with infectious gastroenteritis.93 
The investigators randomly assigned 243 children (aged 
between 6 months and 6 years) with presumed gastroenteritis 
related vomiting to treatment with rectal dimenhydrinate 
or placebo. The dose of dimenhydrinate depended on body 
weight (40 mg ,15 kg bodyweight; 80 mg for 15 to 25 kg 
bodyweight and 120 mg for bodyweights .25 kg). A  dditional 
doses could only be given in case of visible excretion of the 
suppository immediately after ad  ministration or in case of 
persistent v  omiting. Children with none or mild d  ehydration 
were included. All children received oral r  ehydration therapy. 
A short-term follow-up visit in the study center was scheduled 
at 18 to 24 hours after treatment. The investigators called 
the families for a telephone interview 7 to 14 days after 
enrollment. There was no change of bodyweight between 
children who received dimenhydrinate or placebo. The mean 
number of vomiting episodes between treatment and the 
follow-up visit was 0.64 in the dimenhydrinate group and Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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1.36 in the placebo group. In total, 69.6% of the children 
in the d  imenhydrinate group versus 47.4% in the placebo 
group were free of vomiting between treatment and the 
follow-up visit. The numbers needed to treat were 2 (95% 
CI: 1–4) to avoid 1 episode of vomiting and 5 (95% CI: 
3–12) for complete cessation of vomiting. Hospital admis-
sion rate, fluid intake, general well-being of the children, 
parental   satisfaction and potential adverse effects, includ-
ing the number of diarrheal episodes, were similar for both 
groups. Sedation occurred in 21.6% children who received 
dimenhydrinate and 18.6% children who received placebo. 
The study showed that dimenhydrinate reduced the frequency 
of vomiting in children with mild dehydration; however, 
the overall benefit was low, because it did not improve oral 
rehydration or clinical outcome.
Promethazine
Promethazine is derived from phenothiazines with p  ronounced 
antihistamine activity.43 It also has anti-  cholinergic and anti-
  dopaminergic activities.88 Promethazine has also been used in 
the management of post-operative nausea and vomiting and 
motion sickness.57,88 The medication is not expensive and can 
also be given orally, rectally, intramuscularly or i  ntravenously 
with a doses of 0.25 mg to 1 mg/kg bodyweight (up to a 
maximum of 25 mg) every 4 to 6 hours as required.43 It is well 
absorbed orally with clinical effects beginning 20   minutes 
after   administration. There has been only one study published, 
that being by Tibbs in 1968 involving 60 children that use 
promethazine and pyrilamine-pentobarbital for the   treatment 
of children with vomiting from gastroenteritis.94 However, 
this study did not include a placebo group and included 
children with a variety of illnesses other than gastroenteritis. 
However, it showed that promethazine was less effective than 
  pyrilamine-pentobarbital for the relief of vomiting.
Since its approval in 1951, serious and often life-
  threatening adverse events; including respiratory   depression; 
over sedation; agitation; hallucinations; seizures; and 
  dystonic reactions have been reported with promethazine 
use in children.95,96 As of 2005, there were 38 cases of 
respiratory depression, apnea, or cardiac arrest reported to 
the Food and Drug Administration (FDA).97 Twenty two of 
them were in children aged 1.5 months to 2 years of age, 7 of 
which died. Nine of these 22 patients received 1 mg or less 
of   promethazine per kilogram of bodyweight, plus another 
drug with respiratory depressant effects. A wide range of 
weight-based doses (0.45 to 6.4 mg per kg) were associated 
with respiratory depression. Serious outcomes, including 
death, disability, life-threatening events, and hospitalization, 
occurred with all routes of administration (oral, rectal, and 
parenteral). Because of this, in late 2004, a “boxed warning” 
was added to the labeling for promethazine hydrochloride 
(Phenergan), including a contraindication for use in children 
less than two years of age and a strengthened warning with 
regard to the use in children two years of age or older. It 
should also not be prescribed to children who are already 
on other drugs with respiratory depressant effects as it may 
further aggravate the effect on respiratory depression.
Dopamine receptor antagonists
Metoclopramide
Metoclopramide is a chlorinated procainamide derivative 
that has been marketed since the 1960s. It acts   primarily as 
a D2 receptor antagonist and also has   parasympathomimetic 
activity with weak 5-HT3 r  eceptor antagonist activity.88 It has 
both central and peripheral actions, and alleviates nausea and 
vomiting by decreasing afferent impulses to the chemorecep-
tor trigger zone,   lowering gastric sphincter tone, stimulating 
gastric motility and a  ccelerating gastric emptying and small 
intestine transit time. It has been used for the prevention of 
chemotherapy related vomiting, post-operative nausea and 
vomiting, and pregnancy associated nausea and vomiting.98 
Two   studies evaluated metoclopramide as a treatment for 
vomiting   associated with gastroenteritis in 96 hospitalized 
children.55,99 The first double blind, randomized, controlled 
study, in 1979, was published by Van Eygen and colleagues.99 
The authors recruited 60 children aged between 2 to 6 years in 
an in-patient setting. The children were randomized to receive 
a suppository that contained placebo (n = 20), domperidone 
30 mg (n = 20) or metoclopramide 10mg (n = 20) at study 
entry repeated up to 3 times throughout the 24 hour period as 
clinically warranted. This study found that metoclopramide 
was more effective than placebo in reducing symptoms of 
nausea and vomiting. No adverse events were reported. 
  However, a second study by Cubeddu and colleagues found 
that although   metoclopramide reduced the number of 
vomiting episodes the results did not reach any statistical 
significance.55 Significantly more   episodes of diarrhea were 
reported during the first 24 hours in the metoclopramide 
group than the placebo group.
Metoclopramide can be given intravenously,   intramuscularly 
or orally at a dose of 0.1 mg/kg (up to a maximum of 10 mg), 
with the onset of action 1 to 3 minutes, 10 to 15 minutes, and 30 
to 60 minutes, respectively.61 The half-life is 5 to 6 hours with a 
duration of action of 1 to 2 hours.61 Reported adverse effects in 
patients who received   metoclopramide included: drowsiness, 
cough, and tremor. Extrapyramidal reactions such as dystonia, Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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a  kathisia and oculogyric crisis are more common in children 
and reported in up to 25% of children.100,101   Extrapyramidal 
reactions occur regardless of the doses, (whether single or 
multiple doses) or routes of administration. Other severe 
reactions such as:   seizures; neuroleptic malignant   syndrome; 
  methemoglobinemia; sulfhemoglobinemia; and   gynecomastia 
have also been reported.102–104
Droperidol
In June 1968 McNeil laboratories submitted a new drug 
  application for droperidol to the FDA. The drug was approved, 
on June 11 1970, for use preoperatively, during induction and 
maintenance for sedation or tranquilization, for anti-anxiety 
activity, and for the reduction of the incidence of nausea and 
vomiting. Droperidol is classified as a short acting butyrophe-
none and a potent D2 receptor antagonist that also has weak 
anti-cholinergic and antihistamine activity.43 It is pharmaco-
logically related to phenothiazines and thought to act both 
centrally and peripherally. Droperidol has been well studied 
as a postoperative antiemetic agent, but there are no studies 
on its efficacy in gastroenteritis related vomiting.105–107 It has a 
good anti-nausea effect although a lesser antiemetic effect.108 
The recommended dose of droperidol for vomiting is 0.05 to 
0.06 mg/kg bodyweight/dose every 4 to 6 hours intramuscularly 
or intravenously and the onset of action is within 3 to 10 minutes 
with a half-life of 2 hours. Droperidol is not recommended in 
children younger than 2 years because its safety and efficacy 
have not yet been established. The side effects of droperidol are 
mainly prolonged CNS depression and e  xtrapyramidal symp-
toms. Sedative effects can last up to 12 hours.109 However, in 
2001, the FDA posted a black box warning that droperidol could 
cause QT prolongation and   torsades de pointes. The warning 
was based on 273 cases reported over a 4-year period.110 Before 
administration of droperidol, a 12-lead electrocardiogram 
should be performed. Furthermore, the patient must have elec-
trocardiographic monitoring for 2 to 3 hours after droperidol 
administration. Manufacturers now only recommend droperidol 
in patients who fail to show a response to other treatments. 
Janssen   Pharmaceuticals has also stopped marketing droperidol 
outside of the United States since 2001. The fallout from the 
black box warning has the been near cessation of droperidol 
use in the United States.111,112
Domperidone
Domperidone was first synthesized in 1974 and acts as a D2 
receptor antagonist. It acts on the chemoreceptor   trigger zone 
and it can also accelerate gastric emptying time.   Domperidone 
has been used for prevention and tr  eatment of post-operative 
nausea and vomiting. There have been two studies that 
included 109 hospitalized children, aged between 8 months to 
10 years old, which examined its antiemetic effect in   children 
with gastroenteritis.99,113 Unfortunately, the enrollment in 
both studies was not limited to patients with g  astroenteritis, 
although both of them demonstrated that domperidone 
  suppositories decreased the symptoms of nausea and 
  vomiting when compared with placebo. Domperidone is now 
only available for oral or   suppository administration because 
cardiac arrhythmias have been reported after high i  ntravenous 
dose   administration; therefore, the intravenous route of 
administration was discontinued.114–116 The recommended 
oral dose is 0.3 to 0.6 mg/kg bodyweight, with a maximum 
of 25 mg three times a day.82 The recommended rectal dose 
is 10 mg, 30 mg and 60 mg twice/day for children age 
,2 years, 2 to 6 years and .6 years, respectively.82;99 After 
oral administration, peak plasma levels of domperidone occur 
after 30 minutes. Peak levels after the rectal   administration of 
suppositories is usually achieved after 1 to 2 hours. Adverse 
effects of domperidone include ventricular arrhythmias and 
cardiac arrest.82 Unlike metoclopramide, which also has 
both c  entral and peripheral effects, domperidone does not 
cause any   significant extrapyramidal adverse effects because 
of its poor penetration into the central nervous system. 
  Domperidone is currently available in many countries and 
there is   worldwide experience in the use of this agent. In the 
past 3 years,   domperidone has been available in the United 
States through a compassionate clearance program.
Prochlorperazine
Prochlorperazine is a phenothiazine derivative that belongs to 
the piperazine class of drugs. It is a weak dopamine r  eceptor 
blocker and depresses the chemoreceptor trigger zone. It 
was first introduced as an antipsychotic in the 1950s and 
subsequently found to be effective for controlling vomiting 
in 1956 and extended its usage in children in 1958.117 It is 
indicated for control of severe nausea and vomiting, but not 
recommended in patients less than 2 years or 9 kg. Its efficacy 
in pediatric gastroenteritis has not been documented. Even in 
adults, only 3 prospective studies are known to exist.57,118,119 
These 3 studies also included vomiting from other causes. 
The authors compared prochlorperazine to promethzine 
or trimethobenzamide. All these 3 studies showed that 
prochlorperazine is more effective than promethazine or 
trimethobenzamide for treating vomiting.
However, the medication is contraindicated in patients 
with hepatic or renal dysfunction. Akathisia and dystonia are 
the most common side effects in both adults and children in Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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up to 44% of patients administered with this medication.57,120,121 
Children with acute illnesses such as gastroenteritis seem 
more susceptible to neuromuscular reactions, particularly 
dystonias, than adults.(122,123) Other adverse effects include: 
drowsiness; depression; neuroleptic malignant syndrome; 
orthostatic hypotension; and prolongation of the QT interval. 
Tremor and tardive dyskinesia can occur after prolonged or 
chronic use, which are usually irreversible.
The recommended oral and rectal dose is 0.1 to 0.2 mg/kg 
bodyweight with a maximum dose of 5 mg once daily to 
three times daily.43 The recommended intramuscular dose is 
0.15 mg/kg bodyweight.43 Intravenous administration is not 
recommended in children. The onset of action following oral 
or rectal administration is 30 to 60 minutes with a half-life 
of 23 hours and duration of action of 3 to 4 hours.
Unclassified antiemetics
Trimethobenzamide
Trimethobenzamide is an unclassified antiemetic   medication. 
Presumably, it acts on the chemoreceptor trigger zone.61 
It is used for the treatment of post-operative nausea and 
v  omiting.43 Regarding its clinical efficacy for treating 
  vomiting in acute gastroenteritis in children, there are only 
2 published randomized trials. The study published by Tibbs 
included 60 patients in a private pediatric clinic present-
ing with vomiting due to either gastroenteritis, pharyngitis 
or tonsillitis compared trimethobenzamide hydrochloride 
s  uppositories with pyrilamine-pentobarbital suppositories.94 
Another study by Ginsburg and colleagues, randomized 
49 children with acute gastritis who had experienced at least 
one episode of vomiting in the preceding 2 hours to receive a 
suppository that contained either t  rimethobenzamide 200 mg 
(n = 24) or placebo (n = 25).124 Both studies received low qual-
ity scores and showed that trimethobenzamide was no more 
effective than placebo, and was less effective than pyrilamine 
  pentobarbital in treating vomiting due to g  astroenteritis.70 
Bardfeld conducted a controlled double-blind study of 
trimethobenzamide, prochlorperazine and placebo in patients 
older than 17 years of age.119 The author concluded that 
intramuscular prochlorperazine was more effective than 
trimethobenzamide for the treatment of nausea and vomiting. 
At the same time trimethobenzamide is no more effective than 
placebo for treating vomiting in gastroenteritis.
The recommended dose of trimethobenzamide is 4 to 
5 mg/kg bodyweight with a maximum of 200 mg up to 3 
to 4 times/day administered orally or rectally. However, 
suppositories are contraindicated in premature or newborn 
infants and were removed from the market due to lack of 
efficacy.125 The injectable form is also contraindicated in 
pediatric patients. The onset of action, following an oral dose, 
is within 10 to 40 minutes with a half-life 3 to 6 hours and 
duration of action of 3 to 4 hours. Adverse reactions include 
extrapyramidal reactions, drowsiness, depression, headache 
and hypotension.
Dexamethasone
Dexamethasone is a potent synthetic member of the 
  glucocorticoid class of steroid hormones. An action via its 
well known effects on eicosanoid metabolism, reduction 
in inflammation and edema is probably the most favored 
  explanation for its antiemetic effects.126 It is seldom   prescribed 
as an antiemetic in acute gastroenteritis but its effective-
ness in chemotherapy induced emesis has been proved by 
r  andomized controlled trial.127 However, until recently there 
has been no randomized-controlled trial to assess it efficacy 
in treating vomiting in acute gastroenteritis. Stork and col-
leagues randomized patients with acute gastroenteritis-related 
vomiting to receive: dexamethasone (47patients) 1 mg/kg 
bodyweight intravenously, (with a maximum dose of up to 
15 mg); ondansetron (46 patients) 0.15 mg/kg bodyweight; or 
placebo (44 patients) normal saline, 10 ml.71 Hospital admis-
sion occurred in nine patients (20.5%) receiving placebo (nor-
mal saline alone), two patients (4.4%) receiving ondansetron, 
and seven patients (14.9%) receiving dexamethasone. There 
were no s  ignificant   differences in number of mean episodes 
of vomiting or repeat visits to health care providers at 24 
and 72 hours in the ondansetron, dexamethasone, or normal 
saline groups. Dexamethasone was not very effective in 
treating acute gastroenteritis related vomiting, nor effective 
for reducing hospital admission in this study.
The numbers of randomized controlled trials for different 
antiemetics, doses and routes of administration, and special 
considerations are summarized in Table 2.
The changing  
of pharmacoepidemiology  
of antiemetic medications
In 2008, Pfeil and colleagues investigated the prescription 
pattern of antiemetic medications in 0 to 9-year-old   children 
with infectious gastroenteritis in several industrialized 
countries during 2005.63 The authors did not only look at the 
percentage of antiemetic prescriptions among patients with 
acute gastroenteritis, they also investigated the d  istribution 
of different antiemetics among the d  ifferent countries. 
Antihistamines or dopaminergic receptor antagonists were 
prescribed preferentially in all countries. In Germany and Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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Canada, dimenhydrinate accounted most of the prescrip-
tions. In the United States, promethazine was the most 
commonly prescribed antiemetic, even though the FDA had 
issued a black box warning. The dopamine receptor antago-
nist d  omperidone was preferred in Spain, France, Italy and 
United Kingdom. The prescription rate of ondansetron was 
0% in Germany, Canada, Spain and Italy, 3% in United Status 
and 6% in United Kingdom. It seems that there is a strong 
  variation among the different countries in the prescription 
pattern. The serotonin receptor antagonist ondansetron was 
prescribed in a small number of patients only. Cost was a bar-
rier because as there was no generic form available at the time. 
F  urthermore, the proof of therapeutic efficacy of ondansetron 
is relatively new.   Physicians are just beginning to adopt the 
use of ondansetron as a strategy for avoiding intravenous 
therapy and   hospitalization for children with   gastroenteritis 
related vomiting. In 2009, the use of a  ntiemetics in children 
between the ages of 1 and 10 years in emergency visits, 
reported to the National   Ambulatory Medical Care Survey 
database, from 2002 to 2006 was p  ublished.128 The database 
included more than 3 million pediatric visits per year to 
emergency departments for acute gastroenteritis. The study 
showed the rate of   prescribed ondansetron increased from 
0.53% in 2002 to 6.42% in 2006. A similar analysis of both 
emergency d  epartment and outpatient visits to academic 
medical centers and   teaching hospitals from 2005 through to 
2008, derived from the University Health System Consortium 
Clinical Database, showed a similar trend.128 Only 0.5% of 
those presenting to emergency departments and those seek-
ing outpatient care for acute gastritis received ondansetron. 
However, the   percentage had grown to 3.43% in emergency 
departments and 3.6% in outpatient care during 2008. After 
the availability of a generic formula of this drug it is antici-
pated that the use of ondansetron will most likely increase.
The essential pillars of good 
treatment of acute gastroenteritis
Oral rehydration therapy is still the key treatment for 
acute gastroenteritis. Many physicians still believe that 
antiemetic medications have no role in the management 
of acute g  astroenteritis. However, after reviewing the 
  existing   literature, it is evident that ondansetron decreases 
the f  requency of vomiting, improves the success and 
  compliance of oral rehydration therapy and decreases the 
rate of i  ntravenous therapy. It can also decrease the rate of 
h  ospitalization. Even though there is no formal economic 
study, judging from the high cost of hospitalization and the 
decreasing cost of the medication, it is likely that o  ndansetron 
can reduce the health care costs in patients presenting with 
acute gastroenteritis. When compared to placebo ondansetron 
does not increase revisited rate. It has a very good safety 
p  rofile and does not have a sedative effect. The only   drawback 
is the increased frequency of diarrhea after its usage; however 
this is usually transient and well tolerated. Although there is 
no study to evaluate parental satisfaction the success of oral 
rehydration therapy always means that the patients can be 
Table 2 Summary of antiemetic drugs
Drug No. of 
RCT
Route/dose Consideration
Ondansetron 7 RCTs PO: 2 mg for Bw 8–15 kg 
4 mg for Bw 15–30 kg 
8 mg for Bw .30 kg 
iv: 0.1–0.15 mg/kg Bw
Minimal adverse effects, with good evidence 
for reduced admission and intravenous 
therapy
Dimenhydrinate 1 RCT PO/PR/iM/iv: 1.25 mg/kg Bw Sedative effect
Promethazine 1 RCT PO/PR/iM/iv: 0.25-1 mg/kg Bw FDA black box warning
Metoclopramide 2 RCTs PO/iM/iv: 0.1 mg/kg Bw High frequency of extra-pyramidal reaction
Droperidol No RCT iM/iv: 0.05–0.06 mg/kg Bw FDA black box warning
Domperidone 2 RCTs PO: 0.3–0.6 mg/kg Bw 
PR: ,2 yr: 10 mg, 2–6yr: 
30 mg, .6 yr: 60 mg
No iv as increase cardiac arrhythmias
Prochlorperazine No RCT PO: 0.1–0.2 mg/kg Bw 
PR: 0.1–0.2 mg/kg Bw 
iM: 0.15 mg/kg Bw
Not recommended if ,2y/iv dosing not 
recommended in pediatric patients
Trimethobenzamide 2 RCTs  PO: 4–5 mg/kg Bw 
PR: 4–5 mg/kg Bw
PR form was removed from the 
manufacture/iM/iv routes not 
recommended in pediatric patients
Abbreviations: Bw, body weight; PO, per os; PR, per rectum; iM, intramuscular; iv, intravenous; FDA, Food and Drug Administration; RCT, randomized controlled trial.Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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managed at home; which is more comfortable for both the 
patients and parents. As vomiting usually lasts for a few days 
one dose of ondansetron is usually enough. An oral dose is 
preferred because it can be easily given and can avoid the 
setting of an intravenous drip, which may be quite painful 
to the patients.
In  2008,  the  European  Society  for  Pediatric 
  Gastroenterology, Hepatology, and Nutrition and the 
E  uropean Society for P  ediatric Infectious Diseases published 
an evidence-based guideline for the management of acute 
gastroenteritis in c  hildren in Europe.129 The statement has 
changed the perspective on antiemetics and comments that 
antiemetics may be of value for selected children with severe 
vomiting. However, the guideline does not clearly state the 
indications and rationales for choosing the different kinds 
of antiemetics. In the future, guidelines should concentrate 
more on the subgroup of patients that can benefit from the 
antiemetics, and which antiemetics could provide the best 
clinical advantages.
The essential pillars of good treatment of acute 
  gastroenteritis always include the followings:130
i.  Use of oral rehydration for dehydration;
ii.  Hypotonic oral rehydration solution;
iii.  Fast oral rehydration over 3 to 4 hours;
iv.  Rapid realimentation with normal feeding;
v.  Use of special formula is unjustified;
vi.  Use of diluted formula is unjustified;
vii.  Continuation of breast feeding at all time;
viii.     Supplement with oral rehydration solution for   ongoing 
losses.
The usage of antiemetic medications in selected patients 
may be another essential pillar.
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